ESA REMS Allows Oncologists A Year To Enroll In Patient Education Program

The Risk Evaluation and Mitigation Strategy for erythropoiesis-stimulating agents announced by FDA Feb. 16 focuses on requiring health care providers to educate patients about the risks and benefits of treatment, but stops short of some more restrictive REMS options such as patient registries or controlled distribution